Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

<p>Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Zev A. Wainberg (15047031) (author)
Drugi avtorji:	Arun S. Singh (15036660) (author), Gottfried E. Konecny (15047034) (author), Kelly E. McCann (15047037) (author), J. Randolph Hecht (15047040) (author), Jonathan Goldman (15047043) (author), Bartosz Chmielowski (15036666) (author), Richard S. Finn (10431048) (author), Neil O'Brien (15047046) (author), Erika Von Euw (15047049) (author), Megan M. Price (15047052) (author), Diego Martinez (15047055) (author), Lisa Yonemoto (15047058) (author), Meghan Brennan (15047061) (author), John A. Glaspy (15047064) (author), Dennis J. Slamon (15047067) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Preclinical Models In vitro models of cancer
Oznake:	Označite Brez oznak, prvi označite!

Cannot write session to /tmp/vufind_sessions/sess_3u6k0127b13snm025rfhnsmhpp